The company Alfacell has created a chemotherapy drug called Onconase. Onconase was recently used in a clinical trial for the treatment of Malignant Mesothelioma.

Unfortunately, Onconase did not meet Alfacell’s predictions for patient survival, it did achieve an overall survival of 10.5 months for the patients involved who had originally not responded to traditional chemotherapy.

Alfacell is confident that the drug Onconase can be used as a secondary treatment for patients with Mesothelioma, and hope in the future that the drug can be used to treat other types of cancer as well.